Georgia Medical Device Clinical Trial Certificate: The 20 Working Day Publication Deadline

1. Key takeaways

The clinical trial registration certificate for medical devices in Georgia is issued by the regulatory authority and published on the websites of the Ministry and the authority within 20 working days after submission of the application. This is the only element in this topic with an explicit statutory working-day deadline, established by Government Resolution No. 386 of October 3, 2023. For sponsors, the 20-working-day clock is the single most reliable planning anchor in the Georgian trial pathway: every other milestone, from ethics opinions to notarized translations, moves at a pace the sponsor partly controls, while the publication deadline is fixed by regulation and can be monitored from the outside. A disciplined sponsor records day one and watches the ministry and authority websites rather than waiting passively for correspondence.

2. Legal basis

1. Government Resolution No. 386 of October 3, 2023 of Georgia: the clinical trial registration certificate is issued by the authority and published on the websites of the ministry and the authority within 20 working days after submission of the application.
2. Article 4 document list: the application and proof of payment of the registration fee; the power of attorney issued by the sponsor (original, or apostilled or consularly authenticated or notarized); the clinical trial plan and the clinical trial protocol (compliant with GCP, with a notarized Georgian translation); preclinical trial materials; the subject information sheet and written informed consent form samples (with a notarized Georgian translation); the case report form (CRF); a copy of the document confirming that trial risks and liability are covered; documents proving that the device is manufactured according to the relevant standards; the written consent of the heads of the participating medical institutions and of the clinical leads; and well-reasoned positive opinions of the local independent ethics committees of each participating institution.
3. Same article: requirement of protection of the rights of vulnerable groups.
4. Referenced standards: the Declaration of Helsinki, ICH GCP and ISO 14155:2020.

3. Expert insights

Insight one: the 20 working days are a publication deadline, and their institutional value lies in a transparency commitment. The provision commits to the time by which the certificate appears on the websites, not to the time by which the review is passed. This design places the authority under a publication obligation and gives the sponsor a predictable time anchor: if nothing appears within 20 working days, the sponsor can query the procedural status on that basis. The distinction between publication and approval should be explained to internal stakeholders so that the deadline is used correctly in project planning and escalation decisions.

Insight two: the 10 items of the document list can be grouped into four classes of responsible parties. The sponsor is responsible for the application, payment proof, power of attorney, protocol, preclinical materials, CRF, risk coverage document and manufacturing standard evidence; the medical institutions are responsible for the written consents of their heads and clinical leads; the ethics committees are responsible for the well-reasoned positive opinions; and the local entity is responsible for the legal representative registration. Splitting the list by responsible party is the precondition for running the four workstreams in parallel rather than in sequence.

Insight three: the qualifier well-reasoned, applied to the ethics opinion, is a substantive requirement rather than a formal one. The list requires that the positive opinion of the ethics committee be well-reasoned, which means a conclusory, stamp-only opinion risks being rejected. Sponsors should engage ethics committees early about the argumentative structure of the opinion, including how the risk-benefit analysis, the vulnerable groups protections and the informed consent process will each be addressed in the reasoning, not merely asserted.

Insight four: the fee and authentication requirements deserve early attention because they are administrative bottlenecks, not legal ones. The document list requires proof of payment of the registration fee and a power of attorney from the sponsor in original form, or apostilled, consularly authenticated or notarized. None of these items involves scientific judgment, yet each depends on external parties, banks and notaries, whose timelines the sponsor does not control. Missing payment proof or an unauthenticated power of attorney can hold an otherwise complete dossier at the door, and because the 20-working-day publication clock runs from submission, incomplete administrative documents translate directly into lost calendar time.

Two further items on the list reward early planning. The requirement that the device be manufactured according to the relevant standards links the trial dossier to the quality system file, so the manufacturing evidence should be assembled from the technical documentation rather than drafted afresh. And the written consents of the heads of the participating medical institutions and of the clinical leads are signature-dependent documents in hospital environments, where approvals move at administrative speed; scheduling those signatures in the first week of preparation, rather than the last, routinely saves weeks.

4. Practical recommendations

1. Run document preparation in parallel across the 4 classes of responsible parties instead of waiting for each workstream to finish serially.
2. Start the notarized Georgian translations of the protocol and informed consent forms early; this is the most time-consuming link in the chain.
3. Agree the opinion format with the ethics committees in advance to ensure the opinions are well-reasoned.
4. Record working day 1 at submission; if publication has not occurred after 20 working days, initiate a procedural inquiry.
5. Archive the published certificate page as dated evidence, since the publication date itself carries legal significance for downstream planning.

5. Verification checklist

• □ 10 documents prepared under the 4-party division of labor
• □ Notarized translations of protocol and informed consent forms completed
• □ Ethics opinion format agreed in advance
• □ Submission date recorded and 20-working-day tracking started
• □ Copy of the risk and liability coverage document obtained
• □ Published certificate page archived as dated evidence

Regulatory information verified as of October 30, 2026

This English edition is provided by GRZAN, the international regulatory translation service of the GRZAN global compliance desk. GRZAN translates medical device regulatory guidance for manufacturers, importers and authorized representatives preparing documentation for Eurasian, Caucasian and EU-aligned markets. For translation, regulatory monitoring or compliance support inquiries, contact info@grzanglobal.com.